Bladder Cancer Clinical Trial

Disclaimer:

This video is based on public information and is not IRB approved. The images and description in this video do not reflect the opinion of the study sponsor or principal investigators. This is meant for educational purposes, only for the general public.

‍

The SunRISe-3 clinical trial is for patients with non-muscle invasive bladder cancer.

‍

In this study, all participants will have the bladder tumor removed through a procedure called TURBT.  Participants are then randomized to receive bladder infusions with either BCG, TAR/gemcitabine chemotherapy, or both – TAR/gemcitabine chemotherapy with cetrelimab.

‍

FAQs:

‍

How long will the trial last, and what are the expected timeframes for participants to see results or outcomes from the treatments?

Participants will see results and outcomes shortly after the study reaches Study Completion on September 18, 2030. 

‍

Are there any specific criteria for determining whether a participant will receive one treatment option over another, or is it purely random selection?

There are no specific criteria. The study is designed to assign treatments to patients at random.

‍

Are there any restrictions or guidelines for participants regarding other concurrent treatments or medications they may be taking during the trial period, and could these impact the study results?

Yes. You can review this by reading through the eligibility criteria on the CTG study listing. We can also help connect you to the team via the trial form above.